Summer 2027

Technology Intern

Updated on 7/23/2026

Marshall Wace

Marshall Wace

501-1,000 employees

Global provider of alternative investments

Compensation Overview

$72.12/hr

+ Discretionary Bonus

New York, NY, USA

In Person

On-site in New York City; no remote work.

Category
Software Engineering (1)

Get referred to Marshall Wace

Find people who can refer or advise you

Requirements
  • Location: New York, fully in-office (no remote work) for the internship period.
  • Dates: 14th June 2027 – 22nd August 2027; available during these dates.
  • Must be an innovative problem solver who can demonstrate inventive and creative use of technology.
  • High-achieving academically.
  • Have actively developed technical, software engineering skills through coursework, previous internships, research, or personal projects.
  • Degree type is not strictly limited to computer science; open to other disciplines.
  • Strong collaboration, entrepreneurialism, and communication skills.
  • Ability to own work end-to-end and work directly with stakeholders across the firm.
Responsibilities
  • Interns will be assigned to selected projects in pairs, reporting to a senior engineer.
  • Work on projects proposed before start; examples include a backtesting framework for a quantitative trading system, horizontally distributed autonomous coding agents, and an AI-driven user behaviour analytics platform.
  • Interns are expected to identify opportunities for impact through technology, design the solution to capture that potential, build it, and work directly with stakeholders to align engineering efforts with value creation (own end-to-end delivery).
  • Interns will receive comprehensive support including mentorship from managers, regular seminars on the MW tech estate, informational sessions with senior leaders, social events, and opportunities to participate in the firm’s charitable activities.
Desired Qualifications
  • Potential opportunity to return full-time as a member of the Technology Graduate Programme after completing studies.
  • High level of creative, entrepreneurial mindset and excellent communication—demonstrated via previous projects, internships, or research (implied as desirable through description).

Marshall Wace provides alternative investment solutions to clients around the world. It uses a global, integrated team to design and manage a range of investment strategies focused on delivering risk-adjusted returns for institutions and other investors. The firm works to build long-term client relationships based on trust and integrity, and emphasizes continuous improvement and fresh thinking to create proprietary value that benefits clients. Its products are different from traditional funds in their emphasis on alternative strategies and customized, research-driven approaches, aiming to achieve better outcomes through disciplined, differentiated investment methods. The goal is to grow client value by offering thoughtful, proprietary investment strategies that align with clients’ needs and risk tolerances.

Company Size

501-1,000

Company Stage

N/A

Total Funding

$8.9B

Headquarters

London, United Kingdom

Founded

1997

Get referred to Marshall Wace

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • DT-101 is in two ongoing Phase 2 major depressive disorder trials.
  • The company raised $140 million Series A a year earlier.
  • Oversubscribed financing signals strong specialist healthcare investor demand.

What critics are saying

  • DT-101 remains Phase 2, so efficacy failure would destroy the thesis.
  • Heavy capital needs before approval raise dilution risk if data disappoints.
  • Neuropsychiatric drug development faces crowded competition and frequent clinical setbacks.

What makes Marshall Wace unique

  • Marshall Wace backed Draig's oversubscribed $65 million Series B.
  • Draig targets neuropsychiatric disorders with DT-101, an AMPA receptor potentiator.
  • Cardiff University and SV Health Investors co-founded Draig in 2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Social Events

Company News

eFinancialCareers
Mar 31st, 2026
Hedge fund Marshall Wace's newest oil PM is an ex-millennium trader.

Hedge fund Marshall Wace's newest oil PM is an ex-millennium trader. 4 hours ago Moving from Millennium to Marshall Wace - two of the biggest hedge funds in the world - is a pretty normal move as far as the industry goes. Sometimes, however, it takes the better part of a decade and a few side gigs. Andrew Dodson joined Marshall Wace last week as a portfolio manager in its oil team, based in its London office. He joined the firm from DV Trading, a derivatives-focused prop trading firm. He was last employed before that by Millennium as a partner (and portfolio manager) back in 2017. Dodson, whose middle name is Philipp, left Millennium to set up his own hedge fund, Philipp Oil. According to Bloomberg, he was aiming for $500m in assets under management for the launch. However - according to UK register companies house - Philipp Advisors LLP, of which Dodson was a founding member, only ever submitted accounts as a dormant company before being struck off in 2022. He was also the only registered individual with the firm, per the FCA. Confusingly, Dodson was also a member of Sealark LLP, which traded as Philipp Oil for around 18 months in 2018/2019, again per the FCA. Its last full-year accounts, covering 2018, indicate turnover of less than £850k and average profit per member of around £43k. Perhaps Dodson should have stayed at Millennium - the fund has developed a reputation in recent years of fronting some of its star traders with $1bn+ investments to start their own hedge funds. Dodson is not the only new face at Marshall Wace this month. Chet Johal joined the firm this week in London as a portfolio manager from Balyasny, where he spent five years in various analyst and associate roles. And Alexis Wagener joined in New York as a senior credit analyst, having spent two years as a senior associate at Citadel in the city. Marshall Wace declined a request to comment. Dodson did not respond to a request for comment. Have a confidential story, tip, or comment you'd like to share? Contact: +44 7537 182250 (SMS, WhatsApp or voicemail). Telegram: @SarahButcher. Signal: sarahbutcher.22 Click here to fill in our anonymous form, or email [email protected]. Bear with us if you leave a comment at the bottom of this article: comments are moderated intermittently by human beings. Sometimes these humans might be asleep, or away from their desks, so it may take a while for your comment to appear. You must take sole responsibility for comments you post on this site. We will take reasonable steps to weed out anything that we consider to be offensive or inappropriate. The essential daily roundup of news and analysis read by everyone from senior bankers and traders to new recruits. Boost your career. Find thousands of job opportunities by signing up to eFinancialCareers today. Top Articles

BioSpace
Mar 9th, 2026
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

(Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to

MarketScreener
Feb 13th, 2026
Opus Genetics raises $25M to advance gene therapy programmes for inherited retinal diseases

Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, has announced a $25 million private placement led by Adage Capital Management, with participation from Trails Edge Capital Partners and Marshall Wace. The North Carolina-based company will issue 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, convertible into common stock subject to stockholder approval. The financing is expected to close on 18 February 2026. Proceeds will fund clinical programmes for gene therapy candidates targeting various retinal disorders, including OPGx-LCA5 and OPGx-BEST1. Combined with its year-end 2025 cash balance of $70 million, the company expects to fund operations into the first half of 2028. Opus Genetics did not use a placement agent for the offering.

MarketScreener
Feb 13th, 2026
Opus Genetics Announces $25 Million Private Placement

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 -- Opus Genetics, Inc. , a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with...

MedPath
Feb 4th, 2026
MedPath - Medical Intelligence Platform

Comprehensive medical intelligence platform providing access to clinical trials, drug data, patents, scientific literature, and research insights.